Roopa Industries Ltd
Incorporated in 1985, Roopa Industries Ltd is in the business of TPP and its allied products[1]
- Market Cap ₹ 35.8 Cr.
- Current Price ₹ 45.5
- High / Low ₹ 86.3 / 41.3
- Stock P/E 18.6
- Book Value ₹ 23.2
- Dividend Yield 0.00 %
- ROCE 12.0 %
- ROE 12.1 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 10.8% over last 3 years.
- Earnings include an other income of Rs.2.08 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 | 31 | 31 | 30 | 19 | 30 | 28 | 29 | 51 | 76 | 70 | 121 | 124 | |
| 29 | 29 | 31 | 28 | 22 | 28 | 26 | 26 | 48 | 72 | 66 | 117 | 120 | |
| Operating Profit | -0 | 2 | -1 | 2 | -3 | 2 | 2 | 3 | 3 | 4 | 4 | 4 | 4 |
| OPM % | -1% | 7% | -3% | 7% | -14% | 8% | 7% | 10% | 7% | 5% | 6% | 3% | 4% |
| 0 | -0 | 3 | 0 | 5 | 0 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 3 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 |
| Tax % | 3% | 11% | 35% | 56% | -22% | 24% | 54% | 24% | 26% | 25% | 30% | 25% | |
| -2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | |
| EPS in Rs | -2.56 | 0.20 | 0.22 | 0.24 | 0.69 | 0.76 | 0.47 | 0.92 | 1.30 | 1.72 | 1.93 | 2.58 | 2.44 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 34% |
| 3 Years: | 33% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 40% |
| 3 Years: | 25% |
| TTM: | 22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 32% |
| 3 Years: | -6% |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 10% |
| 3 Years: | 11% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 5 | 6 | 8 | 10 | 10 |
| 8 | 8 | 8 | 11 | 16 | 15 | 14 | 13 | 12 | 19 | 26 | 33 | 36 | |
| 7 | 8 | 8 | 8 | 10 | 11 | 14 | 21 | 24 | 24 | 23 | 26 | 32 | |
| Total Liabilities | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 | 87 |
| 8 | 8 | 7 | 7 | 6 | 6 | 11 | 10 | 10 | 10 | 9 | 8 | 8 | |
| CWIP | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | 18 | 18 | 22 | 27 | 26 | 28 | 36 | 39 | 46 | 55 | 68 | 78 | |
| Total Assets | 24 | 26 | 25 | 29 | 35 | 36 | 38 | 46 | 49 | 57 | 65 | 76 | 87 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | -1 | -5 | 4 | 2 | -1 | 2 | -0 | 2 | -7 | |
| -0 | -0 | 0 | -0 | 2 | -2 | 1 | 1 | 4 | -1 | 1 | 2 | |
| -0 | -0 | -1 | 2 | 2 | -2 | -3 | -1 | -5 | 2 | -2 | 5 | |
| Net Cash Flow | -0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 66 | 99 | 146 | 233 | 134 | 157 | 147 | 112 | 34 | 43 | 39 |
| Inventory Days | 94 | 143 | 70 | 139 | 217 | 171 | 256 | 409 | 140 | 109 | 168 | 121 |
| Days Payable | 118 | 132 | 100 | 122 | 177 | 123 | 219 | 280 | 86 | 42 | 96 | 56 |
| Cash Conversion Cycle | 65 | 77 | 69 | 164 | 273 | 182 | 194 | 277 | 166 | 101 | 116 | 104 |
| Working Capital Days | 15 | 32 | 69 | 114 | 214 | 108 | 104 | 114 | 37 | 1 | 10 | 36 |
| ROCE % | -4% | 10% | 10% | 10% | 6% | 9% | 9% | 8% | 10% | 13% | 12% | 12% |
Documents
Announcements
-
Report On Re-Lodgement Of Transfer Requests Of Physical Shares Under Special Window
1d - SEBI special-window re-lodgement report (Nov 2025): zero transfer requests received, processed, approved or rejected.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
17 Nov - Submission of Newspaper Paper Publication w.r.t Unaudited financial results of the Company for the second quarter and half year ended 30/09/2025
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Notice to shareholders w.r.t special window for share transfers
- Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2025 14 Nov
-
Board Meeting Outcome for Board Meeting Outcome And Submission Of Unaudited Financial Results
14 Nov - Approved Q2/H1 FY26 unaudited results; H1 profit Rs.74.76 lakhs; Patancheru plant fire Nov 3, 2025, inventory loss being assessed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3][4]
RIL manufactures Bulk Drugs, Drug Intermediates, Nutraceuticals, and fine chemicals. It produces Active Pharmaceutical Ingredients such as Fluconazole, Sildenafil Citrate, Losartan Potassium and Triphenyl Phosphine (which goes into production of Cephalosporins, Statins etc.,) and Nutraceuticals such as Glucosamine salts.
Its products are used in chemical and pharmaceutical industry and supplied globally